Wendt C, Margolin S. Identifying breast cancer susceptibility genes—a review of the genetic background in familial breast cancer. Acta Oncol. 2019;58(2):135–46.

Article  CAS  PubMed  Google Scholar 

Yadav P, et al. Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients. Clin Transl Oncol. 2016;18(7):728–34.

Article  MathSciNet  CAS  PubMed  Google Scholar 

Xu Y, et al. Global trends and forecasts of breast cancer incidence and deaths. Sci Data. 2023;10(1):334.

Article  PubMed  PubMed Central  Google Scholar 

Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Arnold M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23.

Article  PubMed  PubMed Central  Google Scholar 

Xu H, Xu B. Breast cancer: epidemiology, risk factors and screening. Chin J Cancer Res. 2023;35(6):565.

Article  PubMed  PubMed Central  Google Scholar 

Iacoviello L, et al. Epidemiology of breast cancer, a paradigm of the “common soil” hypothesis. In: Seminars in Cancer biology. Elsevier; 2020.

Miedl H, et al. Association of the MDM2 SNP285 and SNP309 genetic variants with the risk, age at onset and prognosis of breast cancer in Central European women: a hospital-based case-control study. Int J Mol Sci. 2019;20(3):509.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sha M, Huang X, Yin Q. MiR-548b-3p inhibits proliferation and migration of breast cancer cells by targeting MDM2. Eur Rev Med Pharmacol Sci. 2020;24(6):3105–12.

PubMed  Google Scholar 

Levav-Cohen Y, Haupt S, Haupt Y. Mdm2 in growth signaling and cancer: mini review. Growth Factors. 2005;23(3):183–92.

Article  CAS  PubMed  Google Scholar 

Agrawal A, et al. Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer. Exp Mol Pathol. 2006;81(2):115–22.

Article  MathSciNet  CAS  PubMed  Google Scholar 

Razi B, et al. Association between MTHFR gene polymorphism and susceptibility to autism spectrum disorders: systematic review and meta-analysis. Res Autism Spectr Disord. 2020;70:101473.

Article  Google Scholar 

Fouchécourt S, et al. Apoptosis of Sertoli cells after conditional ablation of murine double minute 2 (Mdm2) gene is p53-dependent and results in male sterility. Cell Death Differ. 2016;23(3):521–30.

Article  PubMed  Google Scholar 

Momand J, et al. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26(15):3453–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ladanyi M, et al. MDM2 gene amplification in metastatic osteosarcoma. Can Res. 1993;53(1):16–8.

CAS  Google Scholar 

Li X, et al. Competitive ubiquitination activates the tumor suppressor p53. Cell Death Differ. 2020;27:1807–18.

Article  CAS  PubMed  Google Scholar 

Liu B, et al. MDM2-mediated degradation of WRN promotes cellular senescence in a p53-independent manner. Oncogene. 2019;38(14):2501–15.

Article  CAS  PubMed  Google Scholar 

Eslami MM, et al. Factor V Leiden 1691G> a mutation and the risk of recurrent pregnancy loss (RPL): systematic review and meta-analysis. Thromb J. 2020;18(1):1–16.

Article  Google Scholar 

Surekha D, et al. Codon 72 and G13964C intron 6 polymorphisms of TP53 in relation to development and progression of breast cancer in India. Asian Pac J Cancer Prev. 2011;12(8):1893–988.

CAS  PubMed  Google Scholar 

Mitra S, et al. Association of specific genotype and haplotype of p53 gene with cervical cancer in India. J Clin Pathol. 2005;58(1):26–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jain N, et al. Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India. Chest. 2005;128(6):3999–4007.

Article  CAS  PubMed  Google Scholar 

Addala L, et al. P5 3 codon 72 gene polymorphism and risk of Oral squamous cell carcinoma in South Indian population: a case-control study. J Cancer Sci Ther. 2012;4:188–92.

Article  CAS  Google Scholar 

Bond GL, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Can Res. 2006;66(10):5104–10.

Article  CAS  Google Scholar 

Bond GL, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591–602.

Article  CAS  PubMed  Google Scholar 

Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.

Article  PubMed  Google Scholar 

Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.

Article  PubMed  Google Scholar 

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.

CAS  PubMed  Google Scholar 

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

Article  CAS  PubMed  Google Scholar 

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.

Article  CAS  PubMed  Google Scholar 

Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akisik E, Yazici H, Dalay N. ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer. Mol Biol Rep. 2011;38(1):343–8.

Article  CAS  PubMed  Google Scholar 

Paulin FE, et al. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer. 2008;8(1):281.

Article  PubMed  PubMed Central  Google Scholar 

Copson ER, et al. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer. 2006;6(1):80.

Article  PubMed  PubMed Central  Google Scholar 

Campbell IG, Eccles DM, Choong DY. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett. 2006;240(2):195–7.

Article  CAS  PubMed  Google Scholar 

Krekac D, et al. MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. Oncology. 2008;74(1–2):84–7.

Article  CAS  PubMed  Google Scholar 

Knappskog S, et al. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell. 2011;19(2):273–82.

Article  CAS  PubMed  Google Scholar 

Gansmo LB, et al. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. Int J Cancer. 2015;137(1):96–103.

Article  CAS  PubMed  Google Scholar 

Yilmaz M, et al. Significant association of the MDM2 T309G polymorphism with breast cancer risk in a Turkish population. Asian Pac j Cancer Prev APJCP. 2018;19(4):1059.

CAS  PubMed  Google Scholar 

Petenkaya A, et al. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res. 2006;26(6C):4975–7.

CAS  PubMed  Google Scholar 

Piotrowski P, et al. Murine double minute clone 2 309T/G and 285G/C promoter single nucleotide polymorphism as a risk factor for breast cancer: a Polish experience. Int J Biol Markers. 2012;27(2):105–10.

Article  Google Scholar 

Sinilnikova OM, et al. The TP53 Arg72Pro and MDM2 309G> T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2009;101(8):1456–60.

Article  CAS  PubMed  PubMed Central